Point-of-care cell therapy
imec logo

Blog

How point-of-care manufacturing will enable cell therapies to reach the patients who need them

Technological advancements and strategic partnerships are emerging as a solution to the limitations of centralized production of cell therapies.

Summary

Centralized manufacturing in highly specialized facilities has been the dominant model for the manufacturing of cell therapies, particularly autologous CAR-T therapies. However, this model imposes limitations on accessibility and scalability. Decentralized or point-of-care (POC) manufacturing, enabled by technological innovations and strategic collaborations, addresses these challenges to make cell therapies more accessible to patients worldwide.